Baseline Biomarkers Associated with Early Anatomical Response After Faricimab Loading Therapy in Treatment-Naïve Neovascular Age-Related Macular Degeneration. [PDF]
Ikeuchi E +4 more
europepmc +1 more source
Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. [PDF]
Ahmed E +3 more
europepmc +1 more source
Preclinical Ocular Pharmacokinetics and Efficacy of Novel Tivozanib Eye Drops for Neovascular Age-Related Macular Degeneration. [PDF]
Satake K +6 more
europepmc +1 more source
Machine Learning to Predict Outcomes of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration. [PDF]
Wright DM +5 more
europepmc +1 more source
Short-term outcomes of intravitreal faricimab on refractory neovascular age-related macular degeneration patients in China. [PDF]
Zhou F +6 more
europepmc +1 more source
Faricimab 6 mg Versus Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Protocol-Standardised In Silico Study. [PDF]
Panos GD.
europepmc +1 more source
Relative Risk of Neovascular Age-Related Macular Degeneration Following Cataract Surgery. [PDF]
Bellanda V +8 more
europepmc +1 more source
Rapid resolution of submacular hemorrhage in neovascular age-related macular degeneration using pneumatic displacement and faricimab. [PDF]
Ji PX, Herman JE, Sivachandran N.
europepmc +1 more source
Comparative efficacy and safety of Ranibizumab and Aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis. [PDF]
Zhao X, Yang Y.
europepmc +1 more source

